LivaNova’s OSPREY Study Shows Sustained Efficacy in Sleep Apnea Treatment
Event summary
- LivaNova’s OSPREY study, published in Annals of Internal Medicine, demonstrated sustained efficacy of its aura6000™ System for treating moderate to severe obstructive sleep apnea (OSA) over 12 months.
- The study showed clinically significant improvements in apnea-hypopnea index (AHI), oxygen desaturation index (ODI), and patient-reported outcomes (PROs).
- LivaNova received FDA premarket approval (PMA) for the aura6000 System in March 2026, with plans to commercialize a next-generation device in 2027.
The big picture
LivaNova’s OSPREY study provides high-quality evidence supporting the efficacy of its aura6000 System, addressing a significant unmet need in the OSA market. The FDA approval and planned commercialization of a next-generation device underscore LivaNova’s strategic focus on expanding its footprint in neurostimulation therapies. With up to 1 billion people worldwide affected by OSA, the study results could catalyze broader market adoption and competitive differentiation.
What we're watching
- Regulatory Approval
- The pace at which LivaNova secures FDA approval for its next-generation OSA device, featuring MRI compatibility and long-lasting battery technology.
- Market Adoption
- Whether the sustained efficacy data from OSPREY will drive broader adoption of the aura6000 System among patients intolerant to PAP therapy.
- Competitive Dynamics
- How LivaNova’s differentiated neurostimulation technology positions it against existing and emerging treatments for OSA.